Market Cap 40.07B
Revenue (ttm) 15.41B
Net Income (ttm) 1.37B
EPS (ttm) N/A
PE Ratio 22.70
Forward PE 20.37
Profit Margin 8.91%
Debt to Equity Ratio 2.38
Volume 310,816
Avg Vol 1,298,794
Day's Range N/A - N/A
Shares Out 170.30M
Stochastic %K 33%
Beta 1.36
Analysts Strong Sell
Price Target $258.75

Company Profile

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions th...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 919 998 2000
Address:
2400 Ellis Road, Durham, United States
AcceleratorModel_1
AcceleratorModel_1 Jan. 23 at 6:10 AM
$IQV may be time to come back for more
0 · Reply
AcceleratorModel_1
AcceleratorModel_1 Jan. 23 at 5:31 AM
$IQV Been choppy — but ultimately up and to the right for this name. Haven’t touched it since July ‘25 earnings for a 14% 1 day return. Not looking for a hockey stick here, just a continuation
0 · Reply
rottieluvr3
rottieluvr3 Jan. 16 at 7:43 PM
$IQV This recently broke resistance, but just barely. Once there is confirmation of a breakout, I’m a buyer.
1 · Reply
ZacksResearch
ZacksResearch Jan. 15 at 3:26 PM
Data is becoming the next profit engine in medtech — and these names are leading the charge. 📊🧠 $MDT, $IQV and $GEHC are showing how analytics, AI, and enterprise data platforms can be monetized into recurring revenue streams, pushing medical devices beyond just hardware. See how data + AI are reshaping revenue models in medtech 👉 https://www.zacks.com/stock/news/2818016/3-medical-device-companies-in-focus-for-monetizing-data-and-analytics?cid=sm-stocktwits-2-2818016-teaser-29098&ADID=SYND_STOCKTWITS_TWEET_2_2818016_TEASER_29098
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 14 at 7:33 PM
$IQV Share Price: $241.99 Contract Selected: Aug 21, 2026 $250 Calls Buy Zone: $18.02 – $22.26 Target Zone: $32.32 – $39.50 Potential Upside: 69% ROI Time to Expiration: 218 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 14 at 10:14 AM
$IQV Current Stock Price: $241.63 Contracts to trade: $240 IQV Jan 16 2026 Call Entry: $2.16 Exit: $3.17 ROI: 47% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Philox
Philox Jan. 8 at 2:02 PM
$IQV just popped up on my possible call screen! Not sure on this one as it seems to have liquidity issues but it is on an uptrend. Anyone have any opinions?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 30 at 5:10 AM
$IQV RSI: 55.89, MACD: 1.5703 Vol: 2.61, MA20: 224.22, MA50: 220.64 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Dec. 29 at 6:24 PM
$IQV just ripped higher — and this move looks earned, not hype. 🚀 IQVIA Holdings shares are up 25.5% in three months, driven by its AWS partnership, a growing R&DS backlog, and buybacks that are lifting its earnings outlook — a powerful combo for confidence. See why retaining IQV stock makes sense right now 👉 https://www.zacks.com/stock/news/2809908/heres-why-you-should-retain-iqv-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2809908-teaser-26674&ADID=SYND_STOCKTWITS_TWEET_2_2809908_TEASER_26674
0 · Reply
ZacksResearch
ZacksResearch Dec. 29 at 5:24 PM
$IQV: Is this a buy with 25.5% gains over the past three months compared to the industry’s 12.1% rise? 📈 🤝 Partnership with AWS enhances its AI capabilities in life sciences, improving efficiency. 📊 R&DS backlog at $32.4B, with $8.1B set to convert in 12 months, and $2.6B in net new bookings. 💸 $1.03B in share buybacks over nine months ending in 2025 supports EPS growth. IQV carries a Zacks Rank of #3 (Hold) but faces liquidity challenges with a declining current ratio. Discover the full investment picture here 👉 https://www.zacks.com/stock/news/2809908/heres-why-you-should-retain-iqv-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2809908-body-26676&ADID=SYND_STOCKTWITS_TWEET_2_2809908_BODY_26676
0 · Reply
Latest News on IQV
IQVIA: Increasingly Indispensable In Drug Development

Dec 11, 2025, 1:56 PM EST - 6 weeks ago

IQVIA: Increasingly Indispensable In Drug Development


Dr. William G. Kaelin Jr. joins IQVIA Board of Directors

Nov 5, 2025, 4:15 PM EST - 2 months ago

Dr. William G. Kaelin Jr. joins IQVIA Board of Directors


IQVIA Holdings Inc. (IQV) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 1:52 PM EDT - 3 months ago

IQVIA Holdings Inc. (IQV) Q3 2025 Earnings Call Transcript


IQVIA Reports Third-Quarter 2025 Results

Oct 28, 2025, 7:00 AM EDT - 3 months ago

IQVIA Reports Third-Quarter 2025 Results


IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025

Sep 30, 2025, 4:15 PM EDT - 4 months ago

IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025


ILMN Stock vs. IQV Stock

Sep 26, 2025, 9:40 AM EDT - 4 months ago

ILMN Stock vs. IQV Stock

ILMN


IQVIA: A Positive Long-Term Outlook Despite Trump Legislation

Sep 11, 2025, 2:00 AM EDT - 4 months ago

IQVIA: A Positive Long-Term Outlook Despite Trump Legislation


IQVIA names Michael Fedock as financial chief

Sep 2, 2025, 9:41 AM EDT - 5 months ago

IQVIA names Michael Fedock as financial chief


IQVIA Announces CFO Transition in Early 2026

Sep 2, 2025, 9:00 AM EDT - 5 months ago

IQVIA Announces CFO Transition in Early 2026


The Big 3: BLDR, IQV, LOW

Aug 19, 2025, 12:00 PM EDT - 5 months ago

The Big 3: BLDR, IQV, LOW

BLDR LOW


IQVIA: Q2 Earnings Exceeded My Expectations

Jul 22, 2025, 5:40 PM EDT - 6 months ago

IQVIA: Q2 Earnings Exceeded My Expectations


IQVIA Holdings Inc. (IQV) Q2 2025 Earnings Call Transcript

Jul 22, 2025, 2:00 PM EDT - 6 months ago

IQVIA Holdings Inc. (IQV) Q2 2025 Earnings Call Transcript


IQVIA Reports Second-Quarter 2025 Results

Jul 22, 2025, 7:00 AM EDT - 6 months ago

IQVIA Reports Second-Quarter 2025 Results


IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025

Jul 1, 2025, 7:00 AM EDT - 7 months ago

IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025


IQVIA Launches New AI Agents for Life Sciences and Healthcare

Jun 11, 2025, 7:00 AM EDT - 8 months ago

IQVIA Launches New AI Agents for Life Sciences and Healthcare


IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap?

Jun 10, 2025, 2:23 PM EDT - 8 months ago

IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap?


IQVIA Announces Pricing of Senior Notes

Jun 2, 2025, 4:37 PM EDT - 8 months ago

IQVIA Announces Pricing of Senior Notes


IQVIA Announces Offering of Senior Notes

Jun 2, 2025, 8:10 AM EDT - 8 months ago

IQVIA Announces Offering of Senior Notes


IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials

May 16, 2025, 8:00 AM EDT - 9 months ago

IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials


IQVIA: Q1 Earnings Support Steady Optimism

May 9, 2025, 1:48 PM EDT - 9 months ago

IQVIA: Q1 Earnings Support Steady Optimism


IQVIA Holdings Inc. (IQV) Q1 2025 Earnings Call Transcript

May 6, 2025, 3:04 PM EDT - 9 months ago

IQVIA Holdings Inc. (IQV) Q1 2025 Earnings Call Transcript


IQVIA Reports First-Quarter 2025 Results

May 6, 2025, 7:00 AM EDT - 9 months ago

IQVIA Reports First-Quarter 2025 Results


IQVIA to Announce First-Quarter 2025 Results on May 6, 2025

Apr 21, 2025, 4:15 PM EDT - 9 months ago

IQVIA to Announce First-Quarter 2025 Results on May 6, 2025


IQVIA Releases 2024 Sustainability Report

Feb 20, 2025, 10:06 AM EST - 1 year ago

IQVIA Releases 2024 Sustainability Report


AcceleratorModel_1
AcceleratorModel_1 Jan. 23 at 6:10 AM
$IQV may be time to come back for more
0 · Reply
AcceleratorModel_1
AcceleratorModel_1 Jan. 23 at 5:31 AM
$IQV Been choppy — but ultimately up and to the right for this name. Haven’t touched it since July ‘25 earnings for a 14% 1 day return. Not looking for a hockey stick here, just a continuation
0 · Reply
rottieluvr3
rottieluvr3 Jan. 16 at 7:43 PM
$IQV This recently broke resistance, but just barely. Once there is confirmation of a breakout, I’m a buyer.
1 · Reply
ZacksResearch
ZacksResearch Jan. 15 at 3:26 PM
Data is becoming the next profit engine in medtech — and these names are leading the charge. 📊🧠 $MDT, $IQV and $GEHC are showing how analytics, AI, and enterprise data platforms can be monetized into recurring revenue streams, pushing medical devices beyond just hardware. See how data + AI are reshaping revenue models in medtech 👉 https://www.zacks.com/stock/news/2818016/3-medical-device-companies-in-focus-for-monetizing-data-and-analytics?cid=sm-stocktwits-2-2818016-teaser-29098&ADID=SYND_STOCKTWITS_TWEET_2_2818016_TEASER_29098
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 14 at 7:33 PM
$IQV Share Price: $241.99 Contract Selected: Aug 21, 2026 $250 Calls Buy Zone: $18.02 – $22.26 Target Zone: $32.32 – $39.50 Potential Upside: 69% ROI Time to Expiration: 218 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 14 at 10:14 AM
$IQV Current Stock Price: $241.63 Contracts to trade: $240 IQV Jan 16 2026 Call Entry: $2.16 Exit: $3.17 ROI: 47% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Philox
Philox Jan. 8 at 2:02 PM
$IQV just popped up on my possible call screen! Not sure on this one as it seems to have liquidity issues but it is on an uptrend. Anyone have any opinions?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 30 at 5:10 AM
$IQV RSI: 55.89, MACD: 1.5703 Vol: 2.61, MA20: 224.22, MA50: 220.64 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Dec. 29 at 6:24 PM
$IQV just ripped higher — and this move looks earned, not hype. 🚀 IQVIA Holdings shares are up 25.5% in three months, driven by its AWS partnership, a growing R&DS backlog, and buybacks that are lifting its earnings outlook — a powerful combo for confidence. See why retaining IQV stock makes sense right now 👉 https://www.zacks.com/stock/news/2809908/heres-why-you-should-retain-iqv-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2809908-teaser-26674&ADID=SYND_STOCKTWITS_TWEET_2_2809908_TEASER_26674
0 · Reply
ZacksResearch
ZacksResearch Dec. 29 at 5:24 PM
$IQV: Is this a buy with 25.5% gains over the past three months compared to the industry’s 12.1% rise? 📈 🤝 Partnership with AWS enhances its AI capabilities in life sciences, improving efficiency. 📊 R&DS backlog at $32.4B, with $8.1B set to convert in 12 months, and $2.6B in net new bookings. 💸 $1.03B in share buybacks over nine months ending in 2025 supports EPS growth. IQV carries a Zacks Rank of #3 (Hold) but faces liquidity challenges with a declining current ratio. Discover the full investment picture here 👉 https://www.zacks.com/stock/news/2809908/heres-why-you-should-retain-iqv-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2809908-body-26676&ADID=SYND_STOCKTWITS_TWEET_2_2809908_BODY_26676
0 · Reply
AlgorithmAlphaV3
AlgorithmAlphaV3 Dec. 25 at 5:09 AM
$IQV Downside protection weakens if discipline in balancing growth ambition with capital efficiency, with outcomes shaped by timing and discipline. Uncertainty remains until results confirm narrative.
0 · Reply
topstockalerts
topstockalerts Dec. 24 at 7:31 PM
IQVIA Holdings is entering 2026 with a more constructive and lower-risk outlook, as management expects revenue growth next year to be at least in line with 2025, around 5% reported. Shorter decision cycles and a steadier flow of RFPs point to improving demand visibility, supporting a more predictable environment despite uneven sector growth. The Technology & Analytics Solutions segment is expected to remain resilient, driven by sustained client engagement and continued adoption of analytics and AI tools. Bank of America raised its price target to $260 and reiterated a Buy rating, citing IQVIA’s strong long-term fundamentals and competitive positioning across Phase I–IV services Strategically IQVIA announced a partnership with Amazon Web Services as its preferred cloud provider to enhance its AI-powered clinical trial and healthcare analytics platform. Additional support came from Stifel, which raised its price target and Morgan Stanley which initiated coverage with an Overweight $IQV
0 · Reply
lauren_cooper88
lauren_cooper88 Dec. 12 at 5:47 PM
$IQV Mainz Biomed defending $1.00–$1.01 all day with low ~1.00 high ~1.06 and VWAP ~1.027 tells me this is accumulation, then you add DoctorBox bragging 1,000,000+ users and 10,000,000+ results and I’m not ignoring this coil 🚀
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 4 at 7:15 PM
0 · Reply
RonIsWrong
RonIsWrong Dec. 4 at 7:09 PM
$VKTX $MEDP $IQV $XBI Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics Biotech stocks, including Viking Therapeutics (VKTX), jumped Thursday on a report that the Food and Drug Administration will soon require just one pivotal study to clinch approval for new medical products. The news could give drug and device approvals a boost, but hurt clinical research organizations like Medpace Holdings (MEDP) and Iqvia Holdings (IQV). The companies are responsible for organizing and running the clinical studies necessary to win regulatory approvals. https://www.investors.com/news/technology/medical-stocks-biotech-stocks-research-stocks-fda-clinical-trials/?mod=IBD_FV
0 · Reply
SharePlanner
SharePlanner Dec. 3 at 6:06 PM
Iqvia $IQV doing a great job of holding key support levels on the retest. Strong bounce following a test, hold and bounce off of price level support yesterday. Strong potential for a move back to the upper channel band.
0 · Reply
Estimize
Estimize Dec. 3 at 1:09 PM
Wall St is expecting 3.39 EPS for $IQV Q4 [Reporting 02/18 BMO] http://www.estimize.com/intro/iqv?chart=historical&metric_name=eps&utm_cont
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 5:44 PM
Morgan Stanley has adjusted their stance on IQVIA Hldgs ( $IQV ), setting the rating to Overweight with a target price of 250 → 265.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 1 at 10:47 PM
$IQV Current Stock Price: $228.61 Contracts to trade: $230 IQV Dec 19 2025 Call Entry: $3.70 Exit: $5.94 ROI: 60% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 28 at 7:43 PM
$IQV Share Price: $230.83 Contract Selected: May 15, 2026 $230 Calls Buy Zone: $18.61 – $23.00 Target Zone: $32.90 – $40.21 Potential Upside: 67% ROI Time to Expiration: 167 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 25 at 8:41 PM
$IQV Share Price: $232.34 Contract Selected: May 15, 2026 $230 Calls Buy Zone: $19.89 – $24.57 Target Zone: $36.32 – $44.39 Potential Upside: 72% ROI Time to Expiration: 170 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply